Ginger Breedlove, CNM, PhD, FACNM, is the Nurse-Midwifery Program Director at the University of Kansas and copartner in Midwife Consultants, LLC, Kansas City, Missouri.
Screening and Detection of Ovarian Cancer
Article first published online: 24 DEC 2010
2005 American College of Nurse Midwives
Journal of Midwifery & Womens Health
Volume 50, Issue 1, pages 51–54, January-February 2005
How to Cite
Breedlove, G. and Busenhart, C. (2005), Screening and Detection of Ovarian Cancer. Journal of Midwifery & Womens Health, 50: 51–54. doi: 10.1016/j.jmwh.2004.10.002
- Issue published online: 24 DEC 2010
- Article first published online: 24 DEC 2010
- ovarian cancer;
- ovarian neoplasm;
According to the National Cancer Institute, ovarian cancer is the sixth most common cancer in women and the leading cause of death from gynecologic malignancies. Most often the disease is advanced before symptoms are evident. It is estimated that only 15% to 30% of women in advanced stages will survive 5 years, whereas, of women in stage I at the time of diagnosis, 95% are likely to be alive in 5 years, and most are cured following surgery. Current screening techniques recommended for women with known strong risk factors include combination transvaginal sonography with cancer antigen (CA-125). Transvaginal sonography and serum CA-125 have limited diagnostic predictability. A new early detection method that uses proteomic technology will soon be available. The OvaCheck test, as researchers purport, is a highly specific and sensitive early detection method for ovarian cancer in women with strong risk factors. The Food and Drug Administration has yet to approve nationwide marketing of OvaCheck for early detection, because trials are not yet complete. Anticipated commercial availability is scheduled for early 2005.